HQL (abrdn Life Sciences Investors) Stock Analysis - News
abrdn Life Sciences Investors (HQL) is a publicly traded Financial Services sector company. As of May 21, 2026, HQL trades at $17.23 with a market cap of $537.31M and a P/E ratio of 0.00. HQL moved +1.41% today. Year to date, HQL is +6.90%; over the trailing twelve months it is +38.84%. Its 52-week range spans $10.55 to $18.46. Rallies surfaces HQL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in HQL news today?
abrdn Life Sciences Investors Distributes $0.56, 80% as Long-Term Gains Reinvested at $16.40: abrdn Life Sciences Investors paid a $0.56-per-share distribution on March 31, 2026 to shareholders of record as of February 20, 2026, automatically reinvested at $16.40 per share. The fund estimates the distribution comprised 80% net realized long-term gains and 20% return of capital.
Pittard Christian bought 7.92K (~$133.75K) on Dec 16, 2025.
Saba Capital Management, L.P. sold 41.62K (~$588.55K) on Sep 22, 2025.
Saba Capital Management, L.P. sold 6.99K (~$98.54K) on Sep 19, 2025.
HQL Analyst Consensus
HQL analyst coverage data. Average price target: $0.00.
Common questions about HQL
What changed in HQL news today?
abrdn Life Sciences Investors Distributes $0.56, 80% as Long-Term Gains Reinvested at $16.40: abrdn Life Sciences Investors paid a $0.56-per-share distribution on March 31, 2026 to shareholders of record as of February 20, 2026, automatically reinvested at $16.40 per share. The fund estimates the distribution comprised 80% net realized long-term gains and 20% return of capital.
Does Rallies summarize HQL news?
Yes. Rallies summarizes HQL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is HQL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HQL. It does not provide personalized investment advice.
